1. Home
  2. VRTX vs MO Comparison

VRTX vs MO Comparison

Compare VRTX & MO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$464.65

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Logo Altria Group Inc.

MO

Altria Group Inc.

HOLD

Current Price

$61.06

Market Cap

98.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRTX
MO
Founded
1989
1822
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
115.7B
98.6B
IPO Year
1991
N/A

Fundamental Metrics

Financial Performance
Metric
VRTX
MO
Price
$464.65
$61.06
Analyst Decision
Buy
Buy
Analyst Count
27
8
Target Price
$501.42
$60.57
AVG Volume (30 Days)
1.4M
10.8M
Earning Date
02-12-2026
01-29-2026
Dividend Yield
N/A
6.93%
EPS Growth
N/A
N/A
EPS
14.22
5.24
Revenue
$11,723,300,000.00
$20,166,000,000.00
Revenue This Year
$10.93
$1.44
Revenue Next Year
$8.44
N/A
P/E Ratio
$31.08
$11.67
Revenue Growth
10.33
N/A
52 Week Low
$362.50
$50.08
52 Week High
$519.68
$68.60

Technical Indicators

Market Signals
Indicator
VRTX
MO
Relative Strength Index (RSI) 55.63 63.00
Support Level $429.00 $54.70
Resistance Level $487.52 $62.08
Average True Range (ATR) 12.79 1.15
MACD -2.15 0.55
Stochastic Oscillator 57.70 86.71

Price Performance

Historical Comparison
VRTX
MO

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About MO Altria Group Inc.

Altria comprises Philip Morris USA, US Smokeless Tobacco, John Middleton, Horizon Innovations, and Helix Innovations. Through its tobacco subsidiaries, Altria maintains the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the US with 42% annual share in 2024. Beyond its core business, it holds an 8% interest in the world's largest brewer, Anheuser-Busch InBev and a 41% stake in cannabis manufacturer Cronos. It also acquired vaping company Njoy Holdings in 2023 and operates a joint venture with Japan Tobacco in the heated tobacco category for the US.

Share on Social Networks: